Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer

被引：0
|
作者：
Ying Ma
Qin Feng
Bateer Han
Rong Yu
Zhiyong Jin
机构：
[1] Affiliated People’s Hospital of Inner Mongolia Medical University,Department of Thoracic Surgery
[2] Inner Mongolia Cancer Hospital and Affiliated People’s Hospital of Inner Mongolia Medical University,undefined
来源：
Hereditas | / 160卷
关键词：
High mobility group B1 (HMGB1); Non-small cell lung cancer (NSCLC); Cisplatin; Multidrug resistance (MDR);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer
    Jiao, Pengfei
    Hou, Junna
    Yao, Mengying
    Wu, Jing
    Ren, Gaofei
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2019, 117
  • [22] Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer
    Sienel, W
    Dango, S
    Woelfle, U
    Morresi-Hauf, A
    Wagener, C
    Brümmer, J
    Mutschler, W
    Passlick, B
    Pantel, K
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (06) : 2260 - 2266
  • [23] Periostin secreted from CAF promotes cancer progression and drug resistance in non-small cell lung cancer
    Suzawa, Ken
    Tomida, Shuta
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Toyooka, Shinichi
    [J]. CANCER SCIENCE, 2023, 114 : 433 - 433
  • [24] Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer
    Krysan, Kostyantyn
    Cui, Xiaoyan
    Gardner, Brian K.
    Reckamp, Karen L.
    Wang, Xiaoyan
    Hong, Longsheng
    Walser, Tonya C.
    Rodriguez, Nicole L.
    Pagano, Paul C.
    Garon, Edward B.
    Brothers, John F., II
    Elashoff, David
    Lee, Jay M.
    Spira, Avrum E.
    Sharma, Sherven
    Fishbein, Michael C.
    Dubinett, Steven M.
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2013, 5 (05): : 481 - 496
  • [25] Wnt1 overexpression promotes tumour progression in non-small cell lung cancer
    Huang, Cheng-Long
    Liu, Dage
    Ishikawa, Shinya
    Nakashima, Takashi
    Nakashima, Nariyasu
    Yokomise, Hiroyasu
    Kadota, Kyuichi
    Ueno, Masaki
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (17) : 2680 - 2688
  • [26] Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer
    Xiao, Lu
    Lan, Xiaoying
    Shi, Xianping
    Zhao, Kai
    Wang, Dongrui
    Wang, Xuejun
    Li, Faqian
    Huang, Hongbiao
    Liu, Jinbao
    [J]. CELL DEATH & DISEASE, 2017, 8 : e2803 - e2803
  • [27] FIGNL1 is a potential biomarker of cisplatin resistance in non-small cell lung cancer
    Meng, Chenxu
    Yang, Yang
    Ren, Pengfei
    Ju, Qian
    Jin, Xiangting
    Long, Qihe
    Chen, Xiangyu
    Wang, Xian
    Li, Fanfan
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2022, 37 (03): : 260 - 269
  • [28] SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer
    Shen, Lihua
    Yang, Min
    Lin, Qionghua
    Zhang, Zhongwei
    Miao, Changhong
    Zhu, Biao
    [J]. ONCOLOGY REPORTS, 2016, 35 (05) : 2561 - 2568
  • [29] Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer
    Lu Xiao
    Xiaoying Lan
    Xianping Shi
    Kai Zhao
    Dongrui Wang
    Xuejun Wang
    Faqian Li
    Hongbiao Huang
    Jinbao Liu
    [J]. Cell Death & Disease, 2017, 8 : e2803 - e2803
  • [30] FRS2 promotes the progression of non-small cell lung cancer
    Gao, Jingpeng
    Wang, Li
    Jiang, Yifei
    Qian, Juanjuan
    Mo, Weiqiang
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (02): : 758 - 765
12345